Clinical trials: NYHA Class II-IV Heart Failure
Heart Failure
Warfarin and Antiplatelet Therapy in Chronic Heart Failure
Whether patients with chronic heart failure (CHF) should be anticoagulated is one of the oldest unresolved questions in cardiovascular therapeutics.
- Trial name
- NCT00007683
- Testing
- Warfarin titrated to an INR of 2.5-3.0, Aspirin, Clopidogrel 75
- Where
- 134 sites in United States, Canada and 1 more
- Volunteers
- 1,587 people
- Sponsor
- US Department of Veterans Affairs
Chronic Heart Failure, Heart Failure NYHA Class II
Severe Heart Failure and Homebased Rehabilitation - An Intersectoral Randomized Controlled Trial
The purpose of this study is to investigate the effect of an early, coordinated rehabilitation intervention for patients with severe heart failure in NYHA class III and IV with a ejection fraction of <40% of normal cardiac…
- Conditions
- Chronic Heart Failure, Heart Failure NYHA Class II, Heart Failure NYHA Class III, Heart Failure NYHA Class IV
- Trial name
- NCT01669395
- Testing
- Early homebased rehabilitation after hospital admission, Usual care
- Where
- Denmark
- Volunteers
- 80 people
- Sponsor
- University Hospital, Gentofte, Copenhagen
Chronic Heart Failure
Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure
The study will evaluate the efficacy and safety of both aliskiren monotherapy and aliskiren/enalapril combination therapy as compared to enalapril monotherapy, on morbidity and mortality in patients with chronic heart failure…
- Trial name
- ATMOSPHERE (NCT00853658)
- Testing
- Enalapril, Aliskiren
- Where
- 806 sites in United States, Argentina and 42 more
- Volunteers
- 7,064 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Heart Failure With Reduced Ejection Fraction
Gender-based Differences in the Outcome of Treatment With Aldosterone Antagonists in Patients With Heart Failure
Heart failure (HF) is a major healthcare problem. In patients with Heart Failure with Reduced Ejection Fraction (HFrEF), aldosterone antagonists reduce mortality and hospitalization rate.
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- GBDAL-HF (NCT06233695)
- Testing
- Potassium sparing diuretic
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Alexandria University
Systolic Heart Failure
Repurposing Probenecid as a Positive Inotrope for the Treatment of Heart Failure
Probenecid is an FDA approved drug for the treatment gout and hyperuricemia. It has been used safely in humans for decades for this and other indications.
- Trial name
- ReProsperHF (NCT01814319)
- Testing
- Probenecid 1 gr oral twice daily
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Cincinnati
Heart Failure, Heart Failure With Reduced Ejection Fraction
Gender-Based Differences in Heart Failure Hospitalizations Among Patients With Heart Failure Treated With Spironolactone
Aldosterone antagonists or mineralocorticoid receptor antagonists (MRAs) are used as therapeutic agents for the management of HF with reduced ejection fraction (HFrEF).
- Conditions
- Heart Failure, Heart Failure With Reduced Ejection Fraction, Heart Failure NYHA Class II, Heart Failure NYHA Class III
- Trial name
- NCT06641284
- Testing
- Spironolactone
- Where
- Saudi Arabia
- Volunteers
- 509 people
- Sponsor
- Ahmad Abdullah Salawi
Heart Failure With Preserved Ejection Fraction (HFpEF)
An Open-label Extension Study Evaluating Safety and Tolerability of LCZ696 in Subjects Who Completed PARAGON-HF in Japan.
This study evaluated the safety and tolerability of LCZ696 treatment in Japanese heart failure patients (NYHA Class II-IV) with preserved ejection fraction after CLCZ696D2301 (PARAGON-HF).
- Trial name
- NCT03909295
- Testing
- LCZ696
- Where
- 17 sites in Japan
- Volunteers
- 52 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure, Left Bundle-Branch Block
Mid-Q Response Study
The Mid-Q Response study is a prospective, multi-center, randomized controlled, interventional, single-blinded, post-market study.
- Conditions
- Heart Failure, Left Bundle-Branch Block, Heart Failure With Reduced Ejection Fraction (HFrEF), Heart Failure NYHA Class II
- Trial name
- NCT04180696
- Testing
- aCRT ON, aCRT OFF
- Where
- 61 sites in Brunei, China and 8 more
- Volunteers
- 177 people
- Sponsor
- Medtronic Cardiac Rhythm and Heart Failure